Drug Pipeline News

Livi is a single-use, soft polyurethane foam device cleared by the FDA to absorb semen and vaginal discharge within approximately 60 seconds.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

ENDO-205 is EndoCyclic Therapeutics' lead program and consists of a first-in-class, non-hormonal targeted epeptide therapeutic for endometriosis, according to the company.

Among 2029 women in Scandinavian countries who were followed up for 14 years, vaccine effectiveness was 100%.

Dardik explains how De Novo-cleared AI identifies preterm birth risk in low-risk pregnancies through whole-image analysis.

Kevin Benson highlighted that the TITAN 2 study demonstrates the Altaviva ITNM system as a safe, minimally invasive, and durable solution for real-world patients who have failed prior overactive bladder treatments.

Raquel Dardik explains how the FDA-cleared Delivery Date AI uses unbiased image analysis to provide a precise predicted delivery date without disrupting existing clinical workflows.

The FDA has cleared a cloud-based AI tool that predicts delivery dates solely from ultrasound images.

A prospective observational study found that age did not independently affect bone mineral density response to romosozumab in postmenopausal women.

Sasha Vereecken explains the potential quality of life and sexual worry benefits of investigational ACT for stress urinary incontinence, as well as who may be best suited for the implant.

The label changes to 6 menopausal HRTs "clarify risk considerations for these drugs," according to a statement from the FDA.

If allowed by prescribers, patients can complete pregnancy tests outside of a medical setting, but must complete pre-treatment pregnancy tests in a medical setting, according to the FDA.

Take a quick look at everything you may have missed in January, from our latest video interviews to new clinical trial data to a FAQ on cervical cancer.

New FDA guidance and AACR-bound data highlight Aviva Bio’s progress in developing a differentiated testosterone therapy aimed at reducing breast cancer risk in women.

A single subcutaneous dose of RE104 produced rapid and durable improvements in postpartum depression, supporting advancement into phase 3 development.

The extended approval and contracpetive efficacy during use from 3 to 5 years was based on a multicenter, single-arm, open-label study (NCT04626596) conducted in the United States.

A large systematic review and meta-analysis found no evidence that paracetamol use during pregnancy increases the risk of autism, ADHD, or intellectual disability in children.

A phase 3 trial of oral brexanolone for postpartum depression will continue unchanged following a favorable DSMB safety review.

Screen-guided care using the PreTRM blood test reduced preterm birth–related complications and NICU use.

Check out the biggest approvals in women's health during 2025.

Recent FDA approvals and emerging research highlight how neurokinin receptor antagonists are expanding nonhormonal options for managing vasomotor symptoms.

GSK, Spero Therapeutics, resubmitted an NDA for tebipenem HBr, an oral carbapenem antibiotic, for treating complicated UTIs, supported by phase 3 trial data.

The updated Revi System streamlines management of urgency urinary incontinence, with an easy-to-use design and a strong body of clinical evidence.